Welcome to our dedicated page for IDEX /DE/ SEC filings (Ticker: IEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEX /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEX /DE/'s regulatory disclosures and financial reporting.
IDEX CORP director Katrina L. Helmkamp received an equity award of 1,035 shares of common stock in the form of restricted stock units. The award was granted at a price of $0.00 per share as compensation, not as an open-market purchase.
After this grant, Helmkamp directly holds 14,235 shares of IDEX common stock. Each RSU converts into one share of common stock and vests in full on the earlier of May 6, 2027 and the date of IDEX’s next annual stockholders meeting, provided that meeting occurs at least 50 weeks after the prior year’s meeting and she remains in continuous service through the vesting date.
Gunter Lakecia N reported acquisition or exercise transactions in this Form 4 filing.
IDEX CORP director Lakecia N. Gunter received an equity award of 805 shares of common stock on May 6, 2026. The award is in the form of restricted stock units, each representing a contingent right to one share of IDEX common stock.
The RSUs vest in full on the earlier of May 6, 2027 and the date of IDEX’s next annual stockholders meeting, if that meeting occurs at least 50 weeks after the prior year’s meeting, and only if Gunter continues in service through the vesting date. After this grant, Gunter directly holds 4,925 shares of IDEX common stock.
IDEX Corp director Matthijs Glastra received a stock-based award. On May 6, 2026, he acquired 805 shares of common stock through a grant of restricted stock units at no cash cost, increasing his direct holdings to 1,880 shares. These RSUs vest in full on May 6, 2027 or at the next annual stockholders meeting held at least 50 weeks after the prior year's meeting, contingent on his continuous service.
Disher Stephanie reported acquisition or exercise transactions in this Form 4 filing.
IDEX CORP director Stephanie Disher received an equity award in the form of restricted stock units. On May 6, 2026, she was granted 805 RSUs, each representing a contingent right to receive one share of IDEX common stock at no purchase price.
These RSUs vest in full on May 6, 2027, or on the date of the company’s next annual stockholders meeting if that meeting occurs at least 50 weeks after the prior year’s meeting, subject to her continuous service. Following this award, she holds 1,880 shares of common stock directly.
IDEX CORP director Carl R. Christenson received an equity award of 805 shares of common stock in the form of restricted stock units. These RSUs convert into one share each when they vest. Following this grant, he directly holds 7,156 shares of IDEX common stock.
The RSUs vest in full on the earlier of May 6, 2027, or the date of the company’s next annual stockholders meeting if it occurs at least 50 weeks after the prior year’s meeting, assuming he continues in service through the vesting date.
BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.
IDEX CORP director Mark A. Buthman received an equity award in the form of restricted stock units. On May 6, 2026 he was granted 805 RSUs, each representing a contingent right to receive one share of IDEX common stock.
The RSUs vest in full on the earlier of May 6, 2027 and the date of IDEX’s next annual stockholders meeting, if that meeting is at least 50 weeks after the prior year’s meeting, and only if he remains in continuous service through the vesting date. Following this grant, he directly owns 10,025 shares of common stock.
Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.
IDEX CORP director Mark A. Beck received an equity award in the form of 805 shares of common stock on May 6, 2026, reported at a price of $0.00 per share as a grant.
The award is structured as restricted stock units, each representing one share of common stock, and will vest in full on the earlier of May 6, 2027, or the date of the company’s next annual stockholders meeting if that meeting occurs at least 50 weeks after the prior year’s meeting, subject to his continued service. Following this grant, Beck directly holds 7,755 shares of IDEX common stock.
IDEX Corporation reported the results of its annual stockholder meeting held on May 6, 2026. Stockholders elected four Class I directors—Mark A. Beck, Carl R. Christenson, Katrina L. Helmkamp and Alejandro Quiroz Centeno—to three-year terms ending at the 2029 annual meeting.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Deloitte & Touche LLP as IDEX’s independent registered public accounting firm for 2026.
IDEX Corp ownership update: Vanguard Capital Management reports beneficial ownership of 5,588,265 shares of common stock, representing 7.53% of the class as of 03/31/2026. The filer discloses sole dispositive power over 5,588,265 shares and sole voting power over 733,569 shares.
The Schedule 13G filing lists Vanguard Capital Management and affiliated business divisions as the reporting entity and states the holdings include securities managed for Vanguard funds and client accounts. Signature by Head of Global Fund Administration dated 04/30/2026.
IDEX Corporation reported solid first-quarter 2026 growth. Net sales rose to $886.9 million from $814.3 million, helped by 5% organic growth, favorable currency and contributions from acquisitions. Net income attributable to IDEX increased to $120.0 million from $95.5 million, with diluted EPS up to $1.61 from $1.26.
Adjusted diluted EPS reached $2.00, up from $1.75, reflecting higher volumes in advantaged markets such as data centers, semiconductors, and space and defense within Health & Science Technologies. Gross margin eased slightly to 44.9% from 45.3% as unfavorable mix and price/cost pressure offset productivity gains and volume leverage.
IDEX generated $103.7 million of operating cash flow and $86.0 million of free cash flow, while investing $17.7 million in capital expenditures. The company returned cash to shareholders through $75.6 million of share repurchases and $52.8 million of dividends. The balance sheet showed $586.2 million of cash, total borrowings of $1.88 billion, and ample liquidity with $517.2 million available under its $800 million revolving facility.